Brainomix, an Oxford-based company, has successfully completed a £14M Series C funding round to further develop AI imaging tools for stroke and lung fibrosis treatment. Co-led by healthtech investors like Parkwalk Advisors, the company has pioneered the Brainomix 360 Stroke platform, significantly improving stroke diagnosis and treatment processes in over 300 hospitals worldwide. Furthermore, they’re expanding into lung fibrosis with the Brainomix 360 e-Lung tool, which has FDA approval. Their innovations contribute to better clinical outcomes and enhanced patient care, making substantial impacts in healthcare.
The AI tools developed by Brainomix are already helping patients get fast and accurate diagnosis and treatment for a range of serious conditions.
Studies show that the use of Brainomix 360 Stroke is linked to a 50 per cent rise in patients receiving mechanical thrombectomy.
Collection
[
|
...
]